文献速递肾移植

肾移植受者钙调神经磷酸酶抑制剂副作用患者报告结局量表的开发

Development of a Patient-Reported Outcome Measure of Side Effects for Patients Taking Calcineurin Inhibitors: The FACIT-CNI-Ntx.
PubMed 文献 · Am J Kidney Dis · 2025-01-23

本研究通过定性访谈开发并建立肾移植受者服用钙调神经磷酸酶抑制剂(CNI)副作用患者报告结局(PRO)量表的内容效度。24例参与者中12例完成概念引出访谈,多数报告神经或认知副作用且部分认为最困扰;据此筛选或新写16个条目,精简为13个条目进行认知 debriefing(18例完成),最终形成震颤与认知副作用两个量表,即FACIT-CNI-Ntx。

要点

  • FACIT-CNI-Ntx包含震颤与认知副作用两个量表,共13个条目。
  • 多数参与者报告神经或认知CNI副作用,部分认为最困扰。
  • 量表的信度、效度及反应度尚未评估。

核心结论

  • 新开发的PRO量表FACIT-CNI-Ntx可捕捉肾移植受者服用CNI的重要副作用。

研究设计与样本

  • 定性访谈研究,包括概念引出和认知 debriefing,参与者为肾移植≤5年且正在服用CNI的成人。

主要发现

  • 24例参与者中12例完成概念引出访谈,多数(n=10)报告神经或认知CNI副作用,其中多数(n=6)认为这些是最困扰的不良后果。
  • 基于访谈结果筛选或新写16个条目,精简为13个条目进行认知 debriefing,由18例参与者完成。
  • 条目组织为震颤和认知副作用两个量表。

临床怎么用

  • 该量表可用于肾移植受者服用CNI时副作用的结构化患者报告,但需进一步验证心理测量学属性。

局限性

  • 参与者不能代表所有肾移植受者。
  • 未评估量表的信度、聚合效度、已知组效度及反应度。
  • 症状无法 definitively 归因于CNI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Valid measures of side effects are important to inform clinical use of calcineurin inhibitors (CNIs). This study developed and established the content validity of a patient-reported outcome (PRO) measure to capture side effects among kidney transplant recipients taking CNIs. STUDY DESIGN: Qualitative interviews for concept elicitation and cognitive debriefing. SETTING & PARTICIPANTS: Participants enrolled in the qualitative study were adults who had received a kidney transplant≤5 years earlier and were currently taking a CNI for immunosuppression. ANALYTICAL APPROACH: Concept elicitation interview data were analyzed by developing a codebook from a list of symptoms described by participants that they attributed to CNIs or their immunosuppression regimen and by applying the constant comparative approach separately by 2 coders. The most bothersome and important side effects reported by participants were used to select existing PRO items. Cognitive debriefing examined item comprehensibility, comprehensiveness, and relevance. RESULTS: Among 24 participating patients, 12 underwent concept elicitation interviews. Most participants (n=10) reported neurological or cognitive CNI side effects, and a majority of those (n=6) reported the neurological and cognitive side effects were the most bothersome adverse consequences of therapy. Based on these findings, 16 items were either selected from the Functional Assessment for Chronic Illness Therapy (FACIT) PRO item library or were newly written. These items were refined and reduced to 13 for cognitive debriefing, which was completed by 18 participants. These items were organized into 2 scales: Tremors and Cognitive Side Effects. LIMITATIONS: Though a diverse set of patients participated, they were not representative of all recipients of kidney transplants. The PRO measure's reliability, convergent and known-groups validity, and responsiveness to change were not evaluated. Symptoms could not be definitively attributed to CNIs. CONCLUSIONS: A newly developed PRO measure, the Functional Assessment of Chronic Illness Therapy-Calcineurin Inhibitor-Neurotoxicity (FACIT-CNI-Ntx), captures important side effects among patients receiving CNIs. PLAIN-LANGUAGE SUMMARY: People undergoing kidney transplantation require a lifelong regimen of immunosuppressing medications, including calcineurin inhibitors. Calcineurin inhibitors have side effects that may negatively impact transplant recipients' lives, sometimes interfering with important daily activities. We created a new survey for kidney transplant recipients to report on their experiences with calcineurin inhibitor side effects that we named the Functional Assessment of Chronic Illness Therapy-Calcineurin Inhibitor-Neurotoxicity (FACIT-CNI-Ntx) and that captures important side effects among patients receiving CNIs.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Hurt CN, Greene GJ, Friedewald J, et al. Development of a Patient-Reported Outcome Measure of Side Effects for Patients Taking Calcineurin Inhibitors: The FACIT-CNI-Ntx. Am J Kidney Dis. 2025. PMID: 39863264. doi:10.1053/j.ajkd.2024.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。